Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
CTSO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.71 - $1.61
Previous CloseN/A
Volume86.19K
Average Volume (3M)121.60K
Market Cap
$57.45M
Enterprise Value$103.11M
Total Cash (Recent Filing)$10.20M
Total Debt (Recent Filing)$27.06M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Nov 06, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding62,761,806
10 Day Avg. Volume58,939
30 Day Avg. Volume121,598
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)4.46
Price to Sales (P/S)1.39
P/FCF Ratio-3.37
Enterprise Value/Market Cap1.79
Enterprise Value/Revenue3.08
Enterprise Value/Gross Profit4.24
Enterprise Value/Ebitda-6.25
Forecast
1Y Price Target
$1.00Price Target Upside9.89% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company's efforts to revamp rep accounts and territories in Germany have shown initial success, contributing to growth in Q2.
Revenue GrowthProduct revenues increased by approximately 9% year-over-year and 10% quarter-over-quarter, primarily due to a turnaround in commercial sales in Germany and strong contributions from global distribution partners.
Bears Say
International Regulatory HurdlesHealth Canada has issued a denial for the company’s marketing authorization, and the company plans to file for reconsideration pending the outcome of the FDA review.
Regulatory ChallengesThe company received a denial letter from the FDA regarding the 510(k) de novo application for the use of DrugSorb-ATR during coronary artery bypass grafting surgery.
Regulatory UncertaintyThe company has not disclosed the specific issues with the regulatory filings, making it difficult to evaluate whether a resolution could be reached, leading to skepticism about the appeal's success.
Cytosorbents News
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.71 and its highest was $1.61 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $57.45M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Nov 06, 2025 which is in 50 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on Aug 07, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.08.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.04.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 62,761,806 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went up 12.36%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
Cytosorbents Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (9.89% Upside)
$1.00 (9.89% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.69%
12-Months-Change
Fundamentals
Return on Equity
-68.84%
Trailing 12-Months
Asset Growth
-10.18%
Trailing 12-Months
Company Description
Cytosorbents Corp
Cytosorbents Corporation (CTSO) is a medical technology company focused on developing and commercializing innovative products for critical care and cardiac surgery. The company specializes in blood purification technology, particularly through its flagship product, CytoSorb, which is designed to remove harmful substances from the bloodstream during severe inflammatory conditions. Cytosorbents operates primarily in the healthcare sector, targeting hospitals and medical facilities that require advanced treatment options for patients experiencing life-threatening conditions.
CTSO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment. While there are strong sales growth, successful restructuring efforts, and positive clinical data, the regulatory challenges for DrugSorb ATR and increased operating expenses pose significant concerns.View all CTSO earnings summariesCTSO Stock 12 Month Forecast
Average Price Target
$1.00
▲(9.89% Upside)
Technical Analysis
Ownership Overview
5.78% Insiders
5.56% Mutual Funds
15.72% Other Institutional Investors
69.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---